About this Research Topic
CAR-T cell-mediated immunotherapies have acquired huge and substantial achievements, currently, several CAR-T cell therapies have been approved in the world for certain types of blood cancers, such as leukemia and lymphoma. Immunotherapies using CAR-T cells have also made some progress in solid tumors, including in combination with other treatments. Many other gene-modified immune cell therapy methods have also developed, including CAR-NK, CAR-M, CAR-γδT, TCR-T, and so on. The complex immunosuppressive tumor microenvironment of solid tumors limits the role of CAR T cells. Oncolytic viruses can activate immune cells, including T cells and reverse the suppressive tumor microenvironment, so oncolytic viruses have become an important development direction for the treatment of solid tumors, and three oncolytic viruses have been approved for clinical use in China, USA, Japan, and a variety of more oncolytic viruses are in clinical trials. At present, these very promising treatment methods still need further research, especially in combinatorial regimens, to improve therapeutic effects for solid tumors.
The goal of this topic is to provide a comprehensive view of the current state-of-the-art, imminent and future directions of the fields in order to accelerate the pre-clinical development, clinical translation, and manufacturing of new approaches for cancer immunotherapy, including engineered immune cells, oncolytic viruses, neoantigen vaccines, and so on. We do invite submissions of original research, brief research reports, including case reports, and review articles, including mini-reviews and systematic reviews.
We are especially interested in state-of-the-art immunotherapy methods for solid tumors in the following research areas:
1) Gene-modified immune cell therapy methods, including CAR-T, TCR-T, CAR-NK, CAR-M, CAR-γδT, and others.
2) Developments of oncolytic viruses and oncolytic bacteria
3) Other new immunotherapy methods for solid tumors, including neoantigen vaccines
Please Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this Section and will not be accepted as part of this Research Topic.
The goal of this topic is to provide a comprehensive view of the current state-of-the-art, imminent and future directions of the fields in order to accelerate the pre-clinical development, clinical translation, and manufacturing of new approaches for cancer immunotherapy, including engineered immune cells, oncolytic viruses, neoantigen vaccines, and so on. We do invite submissions of original research, brief research reports, including case reports, and review articles, including mini-reviews and systematic reviews.
We are especially interested in state-of-the-art immunotherapy methods for solid tumors in the following research areas:
1) Gene-modified immune cell therapy methods, including CAR-T, TCR-T, CAR-NK, CAR-M, CAR-γδT, and others.
2) Developments of oncolytic viruses and oncolytic bacteria
3) Other new immunotherapy methods for solid tumors, including neoantigen vaccines
Please Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this Section and will not be accepted as part of this Research Topic.
Keywords: oncolytic virus
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
